Neuraminidase inhibitors for influenza complications--Authors' reply

Affiliations

¹ Division of Epidemiology and Public Health, University of Nottingham, Nottingham NG5 1PB, UK. Electronic address: jvt@nottingham.ac.uk.
² National Heart and Lung Institute, Imperial College, London, UK.
³ Department of Infection, Immunity and Inflammation, University of Leicester, Leicester.

Free article

Comment

Jonathan S Nguyen-Van-Tam et al. Lancet. 2014.

Free article

. 2014 Oct 4;384(9950):1261-2.

doi: 10.1016/S0140-6736(14)61762-1.

¹ Division of Epidemiology and Public Health, University of Nottingham, Nottingham NG5 1PB, UK. Electronic address: jvt@nottingham.ac.uk.
² National Heart and Lung Institute, Imperial College, London, UK.
³ Department of Infection, Immunity and Inflammation, University of Leicester, Leicester.

No abstract available

Comment on

Antivirals for influenza: where now for clinical practice and pandemic preparedness?
Nguyen-Van-Tam JS, Openshaw PJ, Nicholson KG. Nguyen-Van-Tam JS, et al. Lancet. 2014 Aug 2;384(9941):386-7. doi: 10.1016/S0140-6736(14)60726-1. Epub 2014 May 14. Lancet. 2014. PMID: 24837882 No abstract available.
Neuraminidase inhibitors for influenza complications.
Del Mar C, Doshi P, Hama R, Jones M, Jefferson T, Heneghan C, Onakpoya I, Howick J. Del Mar C, et al. Lancet. 2014 Oct 4;384(9950):1260-1. doi: 10.1016/S0140-6736(14)61761-X. Lancet. 2014. PMID: 25283565 No abstract available.